BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib
MUNICH—An “unprecedented improvement” in progression free survival (PFS) was observed in the randomized controlled double-blind phase three SOLO1 study of women with newly diagnosed ovarian cancer who had BRCA1/2 mutations and …
COPENHAGEN, Denmark—Marked prolongation of progression free survival (PFS) in all groups of patients with platinum-sensitive recurrent ovarian cancer was reported at the European Society for Medical Oncology 2016 congress in findings from the double-blind phase 3 European Network of Gynaecological …
LONDON— Researchers have shown that endometrial cancer — and hopefully ovarian cancer too — could potentially be detected much earlier than at present — or even prevented altogether — by looking for ‘silencing’ by DNA methylation of the HAND2 gene: …